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Summary
Background Many causes of vision impairment can be prevented or treated. With an ageing global population, the 
demands for eye health services are increasing. We estimated the prevalence and relative contribution of avoidable 
causes of blindness and vision impairment globally from 1990 to 2020. We aimed to compare the results with the 
World Health Assembly Global Action Plan (WHA GAP) target of a 25% global reduction from 2010 to 2019 in 
avoidable vision impairment, defined as cataract and undercorrected refractive error. 
Methods We did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, 
to October, 2018. We fitted hierarchical models to estimate prevalence (with 95% uncertainty intervals [UIs]) of 
moderate and severe vision impairment (MSVI; presenting visual acuity from <6/18 to 3/60) and blindness (<3/60 or 
less than 10° visual field around central fixation) by cause, age, region, and year. Because of data sparsity at younger 
ages, our analysis focused on adults aged 50 years and older.
Findings Global crude prevalence of avoidable vision impairment and blindness in adults aged 50 years and older did 
not change between 2010 and 2019 (percentage change –0·2% [95% UI –1·5 to 1·0]; 2019 prevalence 9·58 cases per 
1000 people [95% IU 8·51 to 10·8], 2010 prevalence 96·0 cases per 1000 people [86·0 to 107·0]). Age-standardised 
prevalence of avoidable blindness decreased by –15·4% [–16·8 to –14·3], while avoidable MSVI showed no change 
(0·5% [–0·8 to 1·6]). However, the number of cases increased for both avoidable blindness (10·8% [8·9 to 12·4]) and 
MSVI (31·5% [30·0 to 33·1]). The leading global causes of blindness in those aged 50 years and older in 2020 were 
cataract (15·2 million cases [9% IU 12·7–18·0]), followed by glaucoma (3·6 million cases [2·8–4·4]), undercorrected 
refractive error (2·3 million cases [1·8–2·8]), age-related macular degeneration (1·8 million cases [1·3–2·4]), and 
diabetic retinopathy (0·86 million cases [0·59–1·23]). Leading causes of MSVI were undercorrected refractive 
error (86·1 million cases [74·2–101·0]) and cataract (78·8 million cases [67·2–91·4]).
Interpretation Results suggest eye care services contributed to the observed reduction of age-standardised rates of 
avoidable blindness but not of MSVI, and that the target in an ageing global population was not reached. 
Funding Brien Holden Vision Institute, Fondation Théa, The Fred Hollows Foundation, Bill & Melinda Gates 
Foundation,  Lions Clubs International Foundation, Sightsavers International, and University of Heidelberg.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
With rising sociodemographic status and life expectancy, 
many countries around the world are seeing more people 
live into adulthood, increases in the average age of the 
population, and a shift in the disease burden towards 
non-communicable diseases and disabilities. Most of the 
principal causes of vision impairment, including cataract 
and undercorrected refractive error,1 are subject to this 
epidemiological transition2 and carry significant indi-
vidual and societal costs.3,4 Cataract surgery and the 
dispensing of spectacles are among the most cost-
effective health-care interventions currently available.5–7 
Addressing these reversible conditions by scaling up 
existing health-care systems to provide access to cataract 
surgery and spectacles is an important opportunity. To 
highlight this need, the WHO and the International 
Agency for Prevention of Blindness created an initiative 
in 1999 called “Vision 2020: The Right to Sight”. In 2013, 
the World Health Asssembly (WHA) launched a new 
plan, Towards universal eye health: a global action plan 
2014–2019 (GAP).8 It set a global target: to achieve by 2019 
a 25% reduction from the baseline of 2010 in prevalence 
of “avoidable”8 visual impairment, defined as the 
aggregated crude prevalence of cataract and underc-
orrected refractive error (presenting visual acuity <6/18).
Previously, the Vision Loss Expert Group (VLEG) 
reported the results of a systematic review of population-
based studies that reported the prevalence of blindness 
and vision impairment dating from 1980. These studies 
were compiled in a continuously updated database 
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called the Global Vision Database.1,9 WHO used these 
estimates as the basis for their 2019 world report on 
vision, which focused on people-centred eye care as a 
means for health system strengthening,10 and cause-
specific data by region for 2015 were made available 
online.
Since then, the VLEG has conducted a major update of 
the Global Vision Database in collaboration with 
researchers from the Global Burden of Diseases, 
Injuries, and Risk Factors Study (GBD study). Updated 
estimates are of particular interest because of recent 
rapid socioeconomic development, for example in China 
and south Asia. Additionally, the progressive emergence 
of causes of vision impairment such as myopic macular 
degeneration (particularly in China11,12) and diabetic 
retinopathy as significant contributors to the vision 
impair ment burden warrants a global update. With 
ageing populations, it was anticipated that two other 
conditions, glaucoma13 and age-related macular degen-
era tion,14 would continue to be major causes of vision 
impairment. We now have more detailed and repre-
sentative data sources from surveys of eye disease, 
bolstering our ability to track changes over time in 
cataract, undercorrected refractive error, macular 
degeneration, diabetic retinopathy, and glaucoma.
We report global and regional estimates of the burden 
of moderate and severe vision impairment (MSVI) and 
blindness due to cataract, undercorrected refractive 
error, glaucoma, age-related macular degeneration, and 
diabetic retinopathy. We examined temporal, sex, and 
age trends, with a focus on older age groups. We also 
assessed progress against the WHA GAP target of 
25% reduction in avoidable vision impairment between 
2010 and 2019.
Methods
Estimates described here were produced in compliance 
with the Guidelines for Accurate and Transparent Health 
Estimates Reporting.15 
Input data
Preparation of data included first a systematic review of 
published population-based studies of vision impairment 
and blindness by the VLEG, that also included grey 
literature sources. Eligible studies from this review were 
then combined with data from Rapid Assessment of 
Research in context
Evidence before this study
The growing and ageing of populations have led to increasing 
numbers of individuals with moderate or worse vision 
impairment globally. These trends triggered WHO and the 
International Agency for the Prevention of Blindness to create 
an initiative in 1999 called “Vision 2020: The Right to Sight”. 
This initiative set a goal to eliminate avoidable blindness. 
Previous publications by the Vision Loss Expert Group, and by 
the Global Burden of Diseases, Injuries, and Risk Factors Study 
demonstrated that, in 2015, cataract and undercorrected 
refractive error were responsible for the majority of moderate 
or worse vision impairment, and case numbers continued to 
rise over time.
Added value of this study
This study updates global and regional estimates of causes of 
moderate and severe vision impairment and blindness 
through 2020. We examined age-adjusted and sex-adjusted 
differences in the contribution of these causes to vision 
impairment, with a focus on older age groups. We 
incorporated studies from an updated systematic review for a 
total of 376 cause-specific sources. Rapid Assessment of 
Avoidable Blindness studies—key sources of vision loss data 
from low-income and middle-income settings—were 
disaggregated from prevalence for ages 50–99 years into 
5-year age groups, providing more accurate data on age 
patterns. This update also allowed us to assess the World 
Health Assembly 2013 Global Action Plan (WHA GAP) target 
to reduce avoidable vision impairment, which was specifically 
defined as a reduction in moderate or worse vision 
impairment from undercorrected refractive error and cataract 
by 25% between 2010 and 2019.
Implications of all the available evidence
We found that in adults aged 50 years and older there was no 
change in the crude prevalence of avoidable vision impairment 
between 2010 and 2019, and case numbers increased. Cataract 
remained the largest contributor to global blindness in adults 
aged 50 years and older in 2020, with over 15 million individuals, 
approximately 45% of the 33·6 million cases of global blindness. 
Undercorrected refractive error remains the largest contributor 
to global moderate and severe vision impairment (MSVI) in 
adults aged 50 years and older, with over 86 million individuals, 
approximately 42% of the 206 million cases of global MSVI. 
Although less easily treatable, glaucoma, diabetic retinopathy, 
and age-related macular degeneration collectively led to more 
than 19 million cases of moderate or worse vision impairment in 
adults aged 50 years and older in 2020, making these diseases 
important targets for prevention and treatment. 
Age-standardised prevalence was higher in women than in men 
for all modelled causes of moderate or worse vision impairment, 
with the exception of glaucoma for which age-standardised 
prevalence was higher in men. Although the number of affected 
individuals increased for blindness due to all modelled causes, 
age-standardised prevalence for all modelled causes of vision 
except diabetic retinopathy has decreased over the past 
three decades.  This suggests that eye care services did 
successfully reduce age-standardised prevalence, but they did 
not meet the growing need due to ageing and growth of the 
populations.
For the cause-specific data by 
region see http://atlas.iapb.org
For the Global Vision Database 
see https://www.
globalvisiondata.org/
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Avoidable Blindness (RAAB) studies by VLEG and finally 
data from the US National Health and Nutrition 
Examination survey and the WHO Study on Global 
Ageing and Adult Health were contributed by the GBD 
team. These stages are explained in more detail as 
follows. We included population-representative studies 
as data sources for cause-specific vision impairment 
modelling, primarily national and subnational cross-
sectional surveys. RAAB surveys, which sample 
individuals aged 50 years and older, were major sources 
of data for low-income and middle-income settings. 
The VLEG has systematically reviewed scientific 
literature published between 1980 and 2018 by com-
missioning the York Health Economics Consortium, UK, 
to search Embase, SciELO, MEDLINE, WHOLIS, and 
Open Grey, and additional grey literature sources. After 
title and abstract screening, abstracts were sent to 
regional committees of VLEG members to assess quality 
and make final inclusion decisions on whether to admit 
data to VLEG’s Global Vision Database. Additionally, 
the VLEG commissioned the preparation of 5-year age-
disaggregated RAAB data from the RAAB repository.
To meet inclusion criteria, visual acuity data had to be 
measured using a vision chart that could be mapped to 
the Snellen scale; studies based on self-report of vision 
impairment were excluded. We included studies that 
measured either presenting vision impairment (where 
visual acuity was measured using the usual corrective 
lenses a person arrived wearing), or best-corrected vision 
impairment (where a pinhole or lenses with power based 
on refraction were used to address any refractive error), 
or both. We applied WHO criteria for vision impairment 
severity, categorising people according to vision in the 
better-seeing eye on presentation. The categories were 
moderate vision impairment (defined as visual acuity 
of ≥6/60 and <6/18), severe vision impairment (visual 
acuity of ≥3/60 and <6/60), and blindness (visual acuity 
of <3/60 or <10° visual field around central fixation, 
although the visual field definition is rarely utilised in 
population-based eye surveys). We report a composite 
term of MSVI that comprises people meeting either 
moderate or severe visual acuity definitions. We also 
report a composite term of moderate or worse vision 
impairment that comprises people meeting moderate, 
severe, or blind visual acuity definitions.
Data preparation 
The separation of raw data into datasets, including total 
all-cause moderate vision impairment, severe vision 
impairment, and blindness, has been explained in detail 
elsewhere, in addition to a full list of the data sources.16 
Cause-specific analyses are described below.
Presenting vision impairment was the reference 
definition for each level of severity. Undercorrected 
refractive error data were extracted directly from data 
sources where available, and otherwise calculated by 
subtracting best-corrected vision impairment from 
presenting vision impairment prevalence for each level 
of severity in studies that reported both measures for a 
given location, sex, age group, and year. All other causes 
were quantified as part of the best-corrected estimates of 
vision impairment at each level of severity.
We modelled distance vision impairment and blindness 
due to the following causes: cataract, undercorrected 
refractive error, age-related macular degeneration, myopic 
macular degeneration, glaucoma, diabetic retinopathy, 
and other causes of vision impairment (in aggregate). 
Minimum age for inclusion of data for these causes was 
set at 20 years for cataract and diabetic retinopathy; and 
45 years for glaucoma and age-related macular degener-
ation. Other vision impairment estimates were combined 
with less prevalent causes of vision impairment to 
create a residual category (eg, retinopathy of prematurity, 
vitamin A deficiency, trachoma). Trachoma data were 
extracted as a proportion, in which the numerator was 
total cases of trachoma, and the denominator was total 
cases of vision impairment at a given severity level. 
Geographic restrictions were applied so that zero 
prevalence was imputed for non-endemic locations.
Data collected using RAAB methodology were adjusted 
to comprehensive surveys (reference definition) using 
the same adjustment factors as for all-cause MSVI and 
blindness (described in a sister paper on all-cause vision 
loss).16 This approach was used because there were many 
more data available for all-cause moderate vision 
impairment, severe vision impairment, and blindness 
than for each specific cause, allowing for more data-rich 
models.
Disease modelling meta-regression 2.1 modelling
We produced location, year, age, and sex-specific esti-
mates of MSVI and blindness using Disease Modelling 
Meta-Regression (Dismod-MR) 2.1, which is described 
in detail elsewhere.16–18 Global estimates are first 
produced with a mixed effects non-linear model using 
all available data to produce a global model fit as well as 
fixed and random effects. These outputs are passed to 
the GBD super-region level (seven super-regions) as a 
prior, and super-region fits are generated using super-
region input data and the global prior. The super-region 
outputs are passed to the region level (21 regions), then 
to the country level, and finally the subnational level for 
21 countries. Final estimates were generated by 
aggregation, for which the region final was the sum of 
country estimates, etc. To location aggregate (eg, super-
regions or global estimates), we aggregated the most 
granular estimates using straightforward summation of 
cases, which were then used to compute all-age and 
age-standardised rates. For location estimates, we used 
draw-level regional estimates of regional case numbers 
(“draws” from the 1000 posterior runs of the model) and 
summed these to obtain super-region and global case 
numbers. We then summarised the draw level estimates 
by taking the mean across values. No weighting was 
For the RAAB repository see 
http://raabdata.info
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used in the global or regional aggregations. For avoidable 
vision loss we took draw-level regional estimates of case 
numbers for uncorrected refractive error and cataract 
and summed these together.
During data processing, we applied data adjustments if 
we knew there were potential measurement errors using 
a meta-regression tool developed at Institute for Health 
Metrics and Evaluation (IHME) called MR-BRT.17 For 
example, our reference definition for all-cause vision loss 
was presenting visual acuity systematically on the basis 
of the results of a regression analysis comparing the 
prevalence of the two methods. We similarly adjusted for 
studies that used RAAB methodology or non-standard 
severity definitions. Our estimation tool (Dismod) made 
quantification of between-study heterogeneity—the part 
of variance not ascribed to fixed effects or geographical 
random effects–and added uncertainty based on that 
finding. 
Modelling and post-processing steps
Dismod-MR 2.1 models were run for all vision 
impairment by severity (moderate, severe, blindness) 
regardless of cause and, separately, for MSVI and 
blindness due to each modelled cause of vision 
impairment (eg, MSVI due to cataract and blindness due 
to cataract). Then, models of MSVI due to specific causes 
were split into moderate and severe estimates using the 
ratio of overall prevalence in the all-cause moderate 
presenting vision impairment and severe presenting 
vision impairment models. Next, prevalence estimates 
for all causes by severity were scaled to the models of 
all-cause prevalence by severity. This produced final 
estimates by age, sex, year, and location for each 
individual cause of vision impairment by severity. 
Models were iterated until reaching convergence, and 
estimates were calculated with the final 1000 model 
runs, or draws. These draws were used to produce mean 
estimates and 95% uncertainty intervals (UIs), bounded 
by the 25th and 975th values of the ordered 1000 draws.
To assess whether targets of the WHA GAP were 
reached in the 2010–19 period, we aggregated estimates 
for cataract and undercorrected refractive error to create 
the “avoidable vision impairment” category used as a 
metric for assessing whether the GAP target was met.
Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report. All authors had access to all estimates 
presented in the paper, and the corresponding author 
had final responsibility for the decision to submit for 
publication. 
Results
We used 512 data sources to calculate the prevalence of 
categories of distance vision impairment. 376 data sources 
reported cause-specific data disaggregated to include at 
least one of the following: undercorrected refractive error, 
cataract, glaucoma, age-related macular degeneration, 
myopic macular degeneration, or diabetic retinopathy 
(appendix p 7). 230 (61%) of these 376 data sources were 
RAABs.16 Many studies incorporated in the 2017 update1 
have since submitted more granular levels of disaggregated 
data, enabling more precise estimates of the causes of 
global vision impairment in 2020 and their temporal 
changes. Data sources for blindness and MSVI caused by 
myopic macular degeneration were sparse globally with 
the majority of sources from China. For this reason, we 
reported estimates of myopic macular degeneration solely 
for China. Globally, data for children and young adults 
were also sparse, as were data for high-income locations. 
Because of the data sparsity at younger ages, we focused 
our analyses on adults aged 50 years and older.
To assess the success of the WHA GAP to reduce 
avoidable vision impair ment, we calculated the change in 
avoidable vision impairment over the past decade. Crude 
prevalence of all moderate or worse avoidable vision 
impairment between 2010 and 2019 in adults aged 
Moderate and severe vision impairment Blindness
Crude prevalence Number of cases Age-standardised 
prevalence
Crude prevalence Number of cases Age-standardised 
prevalence
All causes 1·9% (0·8 to 3·1) 32·0% (30·5 to 33·5) 0·7% (–0·5 to 1·8) –10·0% (–11·2 to –9·1) 16·5% (15·0 to 17·8) –11·4% (–12·3 to –10·6)
Avoidable* (cataract+ undercorrected 
refractive error)
1·6% (0·4 to 2·8) 31·5% (30·0 to 33·1) 0·5% (–0·8 to 1·6) –14·4% (–15·9 to –13·2) 10·8% (8·9 to 12·4) –15·4% (–16·8 to –14·3)
Cataract 2·9% (1·5 to 4·2) 33·2% (31·4 to 34·9) 1·1% (–0·3 to 2·3) –14·0% (–15·5 to –12·7) 11·4% (9·5 to 13·1) –15·1% (–16·4 to –13·9)
Undercorrected refractive error 0·4% (–1·1 to 1·9) 30·0% (28·1 to 31·9) –0·1% (–1·5 to 1·3) –17·5% (–19·2 to –15·7) 6·9% (4·6 to 9·1) –17·8% (–19·5 to –16·3)
Glaucoma 10·7% (9·2 to 12·3) 43·4% (41·4 to 45·5) 8·0% (6·5 to 9·5) –8·3% (–9·8 to –7·0) 18·7% (16·9 to 20·4) –10·8% (–11·9 to –9·9)
Age-related macular degeneration 7·1% (5·2 to 9·0) 38·7% (36·2 to 41·2) 5·0% (3·2 to 6·7) –9·1% (–11·4 to –7·0) 17·7% (14·8 to 20·4) –11·7% (–13·8 to –9·8)
Diabetic retinopathy 0·8% (–0·9 to 2·6) 30·6% (28·3 to 32·8) –0·4% (–2·1 to 1·2) –6·0% (–8·4 to –3·5) 21·8% (18·7 to 25·0) –6·6% (–9·0 to –4·1)
Residual causes of vision loss 1·8% (0·7 to 3·1) 31·9% (30·4 to 33·5) 0·0% (–0·9 to 1·1) –2·4% (–4·1 to –0·8) 26·4% (24·2 to 28·5) –3·7% (–5·2 to –2·3)
Data in parentheses are 95% uncertainty intervals. Data for all ages are given in the appendix (p 6). Data presented in this table were calculated to assess the success of the World Health Assembly’s global action 
plan to reduce avoidable vision impairment. *Classified as “avoidable” in the global action plan. 
Table 1: Percentage change in crude prevalence of moderate and severe vision impairment and blindness in adults aged 50 years and older between 2010 and 2019
See Online for appendix
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Cases (thousands) Age-standardised prevalence (per 1000)
2020 Percentage change from 
1990 to 2020
2020 Percentage change from 
1990 to 2020
Cataract
Global 15 200 (12700 to 18000) 55·7% (51·4 to 59·9) 8·38 (7·04 to 9·93) –31·7% (–33·2 to –30·1)
Central Europe, eastern Europe, and 
central Asia
266 (211 to 332) –4·3% (–7·3 to –1·4) 1·88 (1·50 to 2·33) –36·1% (–37·5 to –34·6)
High income 456 (367 to 566) 56·0% (48·2 to 64·6) 0·877 (0·702 to 1·08) –22·6% (–24·2 to –21·3)
Latin America and Caribbean 1010 (826 to 1210) 78·4% (73·2 to 83·7) 7·85 (6·42 to 9·48) –43·8% (–44·7 to –42·7)
North Africa and Middle East 756 (593 to 941) 30·0% (24·9 to 35·4) 9·06 (7·13 to 11·4) –53·7% (–55·3 to –52·0)
South Asia 5910 (4990 to 6970) 51·1% (44·7 to 57·6) 22·3 (18·9 to 26·1) –46·4% (–48·1 to –44·5)
Southeast Asia, east Asia, and Oceania 5540 (4620 to 6590) 67·2% (62·5 to 72·5) 9·72 (8·14 to 11·5) –43·8% (–45·6 to –41·6)
Sub-Saharan Africa 1240 (1030 to 1490) 54·4% (51·3 to 57·7) 14·9 (12·4 to 17·8) –30·5% (–31·7 to –29·2)
Undercorrected refractive error
Global 2290 (1790 to 2800) 54·4% (48·7 to 60·6) 1·22 (0·960 to 1·50) –28·7% (–31·1 to –26·0)
Central Europe, eastern Europe, and 
central Asia
16·8 (12·8 to 21·1) 9·0% (5·7 to 12·0) 0·121 (0·0912 to 0·150) –17·0% (–19·2 to –14·6)
High income 46·1 (35·7 to 56·9) 35·1% (29·9 to 40·5) 0·103 (0·079 to 0·128) –23·1% (–24·8 to –21·4)
Latin America and Caribbean 126 (97·5 to 153) 97·3% (91·3 to 103·0) 0·943 (0·731 to 1·14) –31·2% (–32·9 to –29·6)
North Africa and Middle East 84·2 (63·8 to 103) 68·3% (61·5 to 74·7) 0·875 (0·673 to 1·07) –36·1% (–38·5 to –33·9)
South Asia 976 (762 to 1190) 25·8% (19·9 to 32·0) 3·30 (2·59 to 4·00) –52·3% (–54·0 to –50·5)
Southeast Asia, east Asia, and Oceania 933 (728 to 1140) 91·5% (82·8 to 101·5) 1·47 (1·16 to 1·79) –27·9% (–31·0 to –24·3)
Sub-Saharan Africa 111 (84·5 to 136) 91·4% (85·3 to 98·0) 1·14 (0·881 to 1·41) –15·0% (–17·2 to –12·8)
Glaucoma
Global 3600 (2800 to 4410) 61·8% (57·2 to 66·8) 2·04 (1·59 to 2·49) –31·9% (–33·0 to –30·6)
Central Europe, eastern Europe, and 
central Asia
178 (139 to 219) 5·5% (1·9 to 9·3) 1·25 (0·972 to 1·53) –31·4% (–32·8 to –30·0)
High income 785 (622 to 964) 60·3% (53·0 to 69·0) 1·41 (1·12 to 1·74) –23·2% (–24·5 to –21·9)
Latin America and Caribbean 334 (256 to 411) 105·5% (98·4 to 113·6) 2·63 (2·01 to 3·23) –36·2% (–37·6 to –34·8)
North Africa and Middle East 463 (354 to 578) 64·8% (57·6 to 72·3) 5·69 (4·37 to 7·10) –40·9% (–43·0 to –39)
South Asia 577 (439 to 726) 75·7% (65·1 to 86·7) 2·26 (1·71 to 2·83) –38·7% (–41·0 to –36·1)
Southeast Asia, east Asia, and Oceania 754 (575 to 957) 52·4% (44·5 to 61·3) 1·34 (1·02 to 1·67) –48·6% (–51·3 to –45·6)
Sub-Saharan Africa 510 (398 to 628) 70·1% (65·1 to 75·2) 6·64 (5·20 to 8·09) –23·5% (–25·5 to –21·5)
Age-related macular degeneration
Global 1840 (1340 to 2420) 69·8% (64·4 to 75·3) 1·03 (0·755 to 1·36) –28·0% (–30·0 to –25·6)
Central Europe, eastern Europe, and 
central Asia
62·5 (43·2 to 84·0) 21·8% (17·2 to 27·5) 0·437 (0·305 to 0·587) –16·8% (–18·5 to –14·9)
High income 595 (455 to 768) 48·3% (40·8 to 56·3) 1·08 (0·828 to 1·39) –28·6% (–30·0 to –27·3)
Latin America and Caribbean 71·1 (49·1 to 97·1) 142·1% (131·5 to 152·5) 0·550 (0·379 to 0·747) –21·2% (–23·3 to –18·8)
North Africa and Middle East 194 (136 to 264) 105·1% (95·0 to 115·8) 2·23 (1·55 to 2·99) –23·3% (–26·5 to –20·1)
South Asia 296 (199 to 421) 53·4% (42·4 to 65·4) 1·05 (0·717 to 1·47) –41·0% (–44·1 to –37·5)
Southeast Asia, east Asia, and Oceania 492 (340 to 673) 104·0% (91·8 to 116·5) 0·835 (0·578 to 1·14) –27·3% (–31·3 to –22·9)
Sub-Saharan Africa 130 (91·4 to 178) 78·5% (70·2 to 86·5) 1·50 (1·05 to 2·04) –19·1% (–23·0 to –15·7)
Diabetic retinopathy
Global 861 (592 to 1230) 150·9% (143·3 to 159·0) 0·459 (0·316 to 0·658) 14·9% (11·4 to 18·4)
Central Europe, eastern Europe, and 
central Asia
11·9 (7·96 to 17·3) 26·6% (17·8 to 36·4) 0·0842 (0·0565 to 0·121) –6·1% (–11·8 to –0·2)
High income 139 (97·2 to 196) 53·2% (44·2 to 62·2) 0·307 (0·215 to 0·433) –13·7% (–17·6 to –9·7)
Latin America and Caribbean 203 (142 to 283) 130·7% (121·7 to 140·5) 1·50 (1·05 to 2·09) –17·9% (–20·5 to –15·2)
North Africa and Middle East 61·0 (40·1 to 91·8) 169·3% (149·2 to 193·1) 0·621 (0·413 to 0·928) 0·9% (–6·2 to 9·3)
South Asia 152 (101 to 225) 190·7% (162·6 to 222·9) 0·487 (0·330 to 0·708) 17·9% (7·8 to 30·1)
Southeast Asia, east Asia, and Oceania 261 (171 to 387) 286·7% (257·9 to 316·2) 0·406 (0·269 to 0·602) 44·5% (33·1 to 56·3)
Sub-Saharan Africa 33·9 (23·0 to 49·2) 177·4% (162·4 to 192·3) 0·341 (0·234 to 0·498) 25·7% (19·4 to 32·3)
(Table 2 continues on next page)
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50 years and older did not change (percentage change 
of –0·2% [95% UI –1·5 to 1·0]); 2019 prevalence 95·8 
cases per 1000 people [85·1 to 108·0], 2010 prevalence 
96·0 cases per 1000 people [86·0 to 107·]), but it increased 
in all ages by 9·1% (7·6 to 10·7). Total cases of moderate 
or worse avoidable vision impairment increased in people 
aged 50 years and older by 29·2% (27·6 to 30·9) and in all 
ages by 20·8% (19·2 to 22·6) for a composite 211 million 
cases of moderate or worse vision impairment in 2010 to 
254 million cases in 2019. Crude prevalence by cause and 
severity in 2020 is given in the appendix (pp 4–5).
Underlying the overall lack of change in crude 
prevalence of all moderate or worse avoidable vision 
impairment in people aged 50 years and older, avoidable 
MSVI showed little change between 2010 and 2019, with 
an increase of 1·6% (0·4 to 2·8), whereas avoidable 
blindness decreased by –14·4% (–15·9 to –13·2; table 1). 
Similarly, age-standardised prevalence of avoidable MSVI 
showed no change (0·5% [–0·8 to 1·6]), but blindness 
decreased (–15·4% [–16·8 to –14·3]). By contrast, the 
number of cases increased markedly for both avoidable 
MSVI (31·5% [30·0 to 33·1]) and avoidable blind-
ness (10·8% [8·9 to 12·4]).
We then looked at the contribution of individual causes 
to global visual impairment in 2020. Among the global 
33·6 million adults aged 50 years and older who were 
blind in 202016 the leading causes of blindness (table 2) 
were cataract (15·2 million cases [95% UI 12·7–18·0]), 
followed by glaucoma (3·6 million cases [2·8–4·4]), 
undercorrected refractive error (2·3 million cases 
[1·8–2·8]), age-related macular degeneration (1·8 million 
cases [1·3–2·4]), and diabetic retinopathy (0·9 million 
cases [0·6–1·2]). For the estimated 206 million aged 
50 years and older adults with MSVI in 2020,16 the leading 
causes of MSVI (table 3) were undercorrected refractive 
error (86·1 million cases [74·2–101·0]), followed by 
cataract (78·8 million cases [67·2–91·4]), age-related 
macular degeneration (6·2 million cases [5·0–7·6]), 
glaucoma (4·1 million cases [3·2–5·2]), and diabetic 
retinopathy (2·9 million cases [2·1–3·9]).
In terms of relative contribution to age-standardised 
prevalence of total blindness in adults aged 50 years and 
older (table 4), cataract caused 45·5% (41·7–49·0) of all 
global blindness, followed by glaucoma (11·0% [9·3–12·8]), 
undercorrected refractive error (6·6% [5·6–7·8]), age-
related macular degenera tion (5·6% [4·3–7·0]) and 
diabetic retinopathy (2·5% [1·7–3·7]). The leading 
contributor to global age-standardised prevalence of adult 
MSVI was under corrected refractive error (table 4; 41·0% 
[38·0–44·1]), followed by cataract (38·9% [35·6–42·4]), 
age-related macular degeneration (3·0% [2·5–3·5]), 
glaucoma (2·1% [1·7–2·5]), and diabetic retinopathy (1·4% 
[1·0–1·9]).
Overall, prevalence of vision impairment increased 
with age, although the pattern of age-specific prevalence 
varied by cause and severity (figure 1). MSVI prevalence 
was consistently higher than blindness for all causes, 
with the exception of glaucoma and age-related macular 
degeneration at the oldest ages. MSVI due to most causes 
increased from age 50 years onward, although MSVI due 
to undercorrected refractive error increased up to the age 
of around 80 years and decreased thereafter.
Of the explicitly modelled causes of global blindness, 
cataract was the principal cause of global blindness in all 
10-year age groups for ages 50 years and older (figure 2). 
The contribution of glaucoma and age-related macular 
degeneration were greatest in the oldest age group, while 
the contributions of diabetic retinopathy to blindness 
decreased with age. For global MSVI, undercorrected 
refractive error was the principal contributor in the age 
groups 50–59 and 60–69 years, and cataract was the 
principal cause in those aged 70 years and older.
We compared age-standardised prevalence between 
men and women aged 50 years and older for each 
Cases (thousands) Age-standardised prevalence (per 1000)
2020 Percentage change from 
1990 to 2020
2020 Percentage change from 
1990 to 2020
(Continued from previous page)
Residual causes of vision loss
Global 9840 (8200 to 11500) 69·3% (62·0 to 76·5) 5·33 (4·46 to 6·24) –24·2% (–27·3 to –21·3)
Central Europe, eastern Europe, and 
central Asia
647 (545 to 754) 11·7% (8·7 to 14·9) 4·63 (3·92 to 5·38) –22·5% (–23·9 to –21·1)
High-income 551 (461 to 650) 48·5% (43·1 to 54·9) 1·22 (1·03 to 1·44) –16·5% (–18·5 to –14·4)
Latin America and Caribbean 1140 (940 to 1350) 125·2% (117·5 to 133·1) 8·69 (7·16 to 10·3) –25·8% (–27·6 to –24·1)
North Africa and Middle East 788 (631 to 959) 73·7% (65·1 to 82·5) 8·48 (6·79 to 10·4) –35·6% (–38·8 to –32·8)
South Asia 1670 (1370 to 2010) 23·4% (12·1 to 36·5) 5·93 (4·84 to 7·10) –54·2% (–58·5 to –49·7)
Southeast Asia, east Asia, and Oceania 3850 (3230 to 4500) 117·0% (108·1 to 125·6) 6·35 (5·33 to 7·40) –23·0% (–26·2 to –19·8)
Sub-Saharan Africa 1200 (973 to 1440) 54·7% (49·4 to 60·0) 12·9 (10·4 to 15·3) –30·0% (–32·1 to –27·8)
Data in parentheses are 95% uncertainty intervals. Data for all ages are given in the appendix (p 2).
Table 2: Cases and age-standardised prevalence in 2020 for blindness and percentage changes from 1990 to 2020 in adults aged 50 years and older, by 
cause of blindness
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cause of vision impairment and found that age-
standardised prevalence of blindness was greater in 
women for cataract (difference between means: 0·19% 
[0·16 to 0·24]), undercorrected refractive error (0·006% 
[0·003 to 0·01]), age-related macular degeneration 
(0·037% [0·028 to 0·047]), and diabetic retinopathy 
(0·008% [0·005 to 0·001]), and greater in men for 
glaucoma (–0·072 [–0·086 to –0·058]. The same patterns 
were found for sex differences in causes of MSVI (data 
not shown).
When looking at geographical trends, in 2020, cataract 
was the largest contributor to blindness in adults 
aged 50 years and older in all super-regions except for the 
high-income super-region, where the largest contributor 
was glaucoma (table 4). This was primarily driven 
by two regions, western Europe (glaucoma: 32·5% 
[27·3 to 37·3] vs cataract: 11·4% [9·4 to 34·9]) and high-
income Asia Pacific (glaucoma: 33·7% [29·4 to 37·7] vs 
cataract: 20·5% [17·7 to 23·9]). For MSVI (table 4), 
cataract was the leading contributor in western and 
Cases (thousands) Age-standardised prevalence (per 1000)
2020 Percentage change from 
1990 to 2020
2020 Percentage change from 
1990 to 2020
Cataract
Global 78 800 (67200 to 91400) 175·2% (170·9 to 179·5) 43·4 (37·1 to 50·2) 19·2% (17·8 to 20·5)
Central Europe, eastern Europe, and 
central Asia
3050 (2490 to 3620) 49·7% (46·2 to 53·0) 21·3 (17·5 to 25·2) 0·4% (–1·1 to 1·9)
High income 7880 (6660 to 9230) 100·2% (94·0 to 106·5) 14·6 (12·2 to 17·1) –1·8% (–2·8 to –0·7)
Latin America and Caribbean 4350 (3650 to 5090) 208·6% (201·8 to 215·7) 33·9 (28·5 to 39·6) –1·2% (–2·4 to 0·14)
North Africa and Middle East 5020 (4230 to 5920) 181·0% (172·6 to 189·6) 58·1 (49·2 to 68·0) 0·6% (–2·1 to 3·6)
South Asia 27200 (23200 to 31800) 180·7% (171·8 to 189·6) 94·6 (81·1 to 109) 1·7% (–0·3 to 3·6)
Southeast Asia, east Asia, and Oceania 26 800 (23000 to 30900) 235·5% (228·3 to 242·7) 47·1 (40·4 to 54·1) 13·5% (11·7 to 15·3)
Sub-Saharan Africa 4440 (3780 to 5160) 150·8% (146·1 to 156·1) 51·4 (44·0 to 59·3) 11·4% (9·7 to 13·4)
Undercorrected refractive error
Global 86 100 (74200 to 101000) 101·8% (98·9 to 104·9) 45·8 (39·6 to 53·7) –6·9% (–8·0 to –5·9)
Central Europe, eastern Europe, and 
central Asia
6340 (5400 to 7480) 25·8% (23·2 to 28·3) 45·1 (38·5 to 53·1) –4·4% (–5·5 to –3·3)
High income 8940 (7680 to 10400) 69·6% (66·3 to 72·9) 19·4 (16·7 to 22·5) –4·6% (–5·6 to –3·6)
Latin America and Caribbean 5780 (4950 to 6780) 162·3% (158·5 to 165·8) 42·8 (36·8 to 50·0) –7·7% (–8·8 to –6·6)
North Africa and Middle East 4680 (3960 to 5550) 140·5% (134·2 to 147·2) 47·3 (40·2 to 55·4) –10·7% (–13·2 to –8·0)
South Asia 32 100 (27500 to 37900) 94·1% (89·6 to 99·7) 103 (88·2 to 121) –23·4% (–24·9 to –21·9)
Southeast Asia, east Asia, and Oceania 25 000 (21500 to 29300) 143·7% (138·4 to 148·7) 39·4 (33·9 to 45·6) –8·8% (–10·6 to –7·1)
Sub-Saharan Africa 3210 (2730 to 3800) 131·7% (126·7 to 136·4) 31·6 (27·3 to 37·0) 2·4% (0·6 to 4·1)
Glaucoma
Global 4130 (3240 to 5170) 151·2% (147·2 to 155·3) 2·29 (1·80 to 2·86) 8·3% (6·8 to 9·9)
Central Europe, eastern Europe, and 
central Asia
213 (167 to 270) 43·6% (40·0 to 47·6) 1·47 (1·15 to 1·86) –3·0% (–4·7 to –1·4)
High income 596 (467 to 762) 103·2% (95·7 to 111·5) 1·09 (0·853 to 1·39) –0·2% (–1·5 to 1·0)
Latin America and Caribbean 498 (390 to 623) 191·7% (185·2 to 199·2) 3·86 (3·02 to 4·84) –4·7% (–6·1 to –3·1)
North Africa and Middle East 325 (251 to 419) 148·1% (139·1 to 157·7) 3·76 (2·87 to 4·85) –9·7% (–12·8 to –6·5)
South Asia 952 (745 to 1200) 145·2% (136·4 to 154·5) 3·38 (2·66 to 4·21) –12·8% (–15·0 to –10·6)
Southeast Asia, east Asia, and Oceania 1160 (916 to 1450) 251·5% (242·0 to 262·0) 2·01 (1·58 to 2·52) 21·4% (18·3 to 24·8)
Sub-Saharan Africa 391 (306 to 493) 111·9% (107·1 to 116·8) 4·57 (3·61 to 5·69) –4·3% (–6·3 to –2·2)
Age-related macular degeneration
Global 6220 (5030 to 7570) 150·2% (145·9 to 154·8) 3·39 (2·75 to 4·12) 10·6% (8·7 to 12·6)
Central Europe, eastern Europe, and 
central Asia
228 (182 to 282) 51·1% (47·8 to 54·3) 1·57 (1·26 to 1·95) 4·8% (3·13 to 6·51)
High income 738 (584 to 917) 76·8% (70·5 to 83·3) 1·39 (1·11 to 1·72) –9·4% (–11·2 to –7·5)
Latin America and Caribbean 333 (269 to 407) 202·2% (193·0 to 212·2) 2·55 (2·07 to 3·13) 1·5% (–1·2 to 4·5)
North Africa and Middle East 493 (390 to 613) 166·0% (156·5 to 175·6) 5·48 (4·36 to 6·77) –0·5% (–4·0 to 2·8)
South Asia 1220 (968 to 1510) 121·4% (112·8 to 130·2) 4·18 (3·36 to 5·11) –20·5% (–23·0 to –18·0)
Southeast Asia, east Asia, and Oceania 2760 (2210 to 3380) 214·6% (204·7 to 224·4) 4·61 (3·73 to 5·61) 13·8% (10·7 to 17·1)
Sub-Saharan Africa 453 (359 to 565) 132·2% (124·6 to 140·3) 4·96 (3·98 to 6·14) 5·6% (2·3 to 9·0)
(Table 3 continues on next page)
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Cases (thousands) Age-standardised prevalence (per 1000)
2020 Percentage change from 
1990 to 2020
2020 Percentage change from 
1990 to 2020
(Continued from previous page)
Diabetic retinopathy
Global 2950 (2140 to 3950) 129·5% (123·2 to 135·9) 1·59 (1·15 to 2·12) 3·3% (0·4 to 5·8)
Central Europe, eastern Europe, and 
central Asia
134 (94·2 to 183) 21·7% (17·3 to 25·9) 0·942 (0·661 to 1·28) –11·3% (–13·9 to –8·7)
High income 386 (277 to 522) 68·4% (63·5 to 74·1) 0·802 (0·578 to 1·08) –7·7% (–9·7 to –6·0)
Latin America and Caribbean 396 (290 to 533) 185·6% (177·6 to 193·6) 2·97 (2·17 to 4·01) –0·9% (–3·1 to 1·4)
North Africa and Middle East 399 (288 to 540) 115·9% (106·3 to 125·6) 4·14 (3·00 to 5·53) –19·6% (–23·2 to –16·0)
South Asia 389 (279 to 527) 123·7% (114·5 to 134·5) 1·28 (0·921 to 1·72) –15·8% (–19·2 to –12·4)
Southeast Asia, east Asia, and Oceania 1100 (796 to 1500) 182·7% (166·3 to 200·2) 1·79 (1·29 to 2·42) 3·2% (–2·6 to 9·0)
Sub-Saharan Africa 138 (98·6 to 186) 145·3% (138·2 to 152·4) 1·44 (1·04 to 1·92) 9·9% (7·1 to 12·8)
Residual causes of vision loss
Global 28 200 (24100 to 33000) 104·4% (100·3 to 108·5) 15·2 (13·0 to 17·8) –8·3% (–9·7 to –6·9)
Central Europe, eastern Europe, and 
central Asia
4180 (3540 to 4950) 34·6% (31·9 to 37·5) 29·1 (24·7 to 34·3) –5·7% (–7·0 to –4·4)
High income 3060 (2570 to 3630) 82·6% (77·6 to 88·5) 6·32 (5·34 to 7·50) –1·6% (–2·9 to –0·3)
Latin America and Caribbean 2710 (2260 to 3230) 176·9% (171·1 to 183·2) 20·5 (17·1 to 24·3) –7·6% (–8·9 to –6·3)
North Africa and Middle East 1090 (890 to 1330) 112·1% (98·8 to 124·5) 11·6 (9·40 to 14·1) –22·1% (–26·7 to –17·6)
South Asia 6900 (5780 to 8250) 141·1% (132·4 to 151·1) 22·9 (19·5 to 27·0) –5·7% (–8·5 to –2·8)
Southeast Asia, east Asia, and Oceania 7850 (6780 to 9100) 158·1% (148·7 to 167·5) 12·7 (11·0 to 14·7) –5·9% (–8·7 to –3·1)
Sub-Saharan Africa 2410 (2020 to 2880) 49·0% (42·0 to 56·0) 24·7 (20·8 to 29·2) –32·4% (–35·5 to –29·3)
Data in parentheses are 95% uncertainty intervals. Data for all ages are given in the appendix (p 3).
Table 3: Cases and age-standardised prevalence in 2020 for moderate and severe vision impairment and percent changes from 1990 to 2020 in adults 
aged 50 years and older, by cause of vision impairment
Cataract Undercorrected 
refractive error
Glaucoma Age-related macular 
degeneration
Diabetic retinopathy Residual causes of 
vision loss
Blindness  
Global 45·4% (41·7–49·0) 6·6% (5·6–7·8) 11% (9·3–12·8) 5·6% (4·3–6·7) 2·5% (1·7–3·7) 28·9% (26·5–31·5)
Central Europe, eastern Europe, and 
central Asia
22·4% (19·1–25·9) 1·4% (1·2–1·8) 14·8% (12·3–17·3) 5·2% (3·8–6·7) 1·0% (0·7–1·5) 55·1% (51·0–59·6)
High income 17·5% (14·9–20·5) 2·1% (1·7–2·5) 28·2% (24·0–32·3) 21·6% (17·5–26·1) 6·2% (4·2–8·8) 24·5% (21·6–27·8)
Latin America and Caribbean 35·4% (31·4–39·8) 4·3% (3·6–5·0) 11·8% (9·7–13·9) 2·5% (1·8–3·2) 6·8% (4·5–9·6) 39·2% (35·5–43·4)
North Africa and Middle East 33·6% (29·4–38·0) 3·3% (2·7–3·8) 21·1% (17·7–24·5) 8·3% (6·2–10·5) 2·3% (1·5–3·6) 31·5% (27·8–36·0)
South Asia 63·1% (59·4–66·8) 9·4% (7·9–10·9) 6·4% (5·2–7·7) 3·0% (2·1–4·0) 1·4% (0·9–2·1) 16·8% (15·0–18·8)
Southeast Asia, east Asia, and Oceania 48·3% (44·5–52·1) 7·3% (6·2–8·5) 6·7% (5·5–7·9) 4·2% (3·0–5·4) 2·0% (1·3–3·0) 31·6% (29·0–34·3)
Sub-Saharan Africa 39·8% (35·9–43·9) 3·1% (2·6–3·6) 17·8% (15·1–20·6) 4·0% (3·0–5·1) 0·9% (0·6–1·4) 34·4% (31·4–37·7)
Moderate and severe vision impairment
Global 38·9% (35·6–42·4) 41% (38·0–44·1) 2·1% (1·7–2·5) 3·0% (2·5–3·5) 1·4% (1·0–2·0) 13·6% (12·3–15·2)
Central Europe, eastern Europe, and 
central Asia
21·4% (18·8–24·2) 45·3% (42·0–48·6) 1·5% (1·2–1·8) 1·6% (1·3–1·9) 1·0% (0·7–1·3) 29·3% (26·2–32·5)
High income 33·5% (29·8–37·2) 44·5% (41·1–48·0) 2·5% (2·0–3·1) 3·2% (2·7–3·8) 1·9% (1·3–2·5) 14·5% (12·7–16·8)
Latin America and Caribbean 31·8% (28·4–35·3) 40·2% (37·1–43·4) 3·6% (3·0–4·4) 2·4% (2·0–2·8) 2·8% (2·0–3·8) 19·2% (17·0–21·8)
North Africa and Middle East 44·6% (40·6–48·8) 36·3% (32·7–39·8) 2·9% (2·3–3·6) 4·2% (3·5–5·0) 3·2% (2·3–4·3) 8·9% (7·6–10·6)
South Asia 41·3% (37·8–45) 44·9% (41·3–48·1) 1·5% (1·2–1·8) 1·8% (1·5–2·2) 0·6% (0·4–0·8) 10% (8·9–11·2)
Southeast Asia, east Asia, and Oceania 43·8% (40·4–47·2) 36·6% (33·7–39·7) 1·9% (1·5–2·3) 4·3% (3·6–5·0) 1·7% (1·2–2·3) 11·8% (10·8–13·0)
Sub-Saharan Africa 43·3% (39·8–46·8) 26·7% (24·4–29·0) 3·9% (3·2–4·8) 4·2% (3·5–4·9) 1·2% (0·9–1·6) 20·8% (18·7–23·0)
Data in parentheses are 95% uncertainty intervals. 
Table 4: Relative percentage contribution of each cause to age-standardised prevalence of blindness and moderate and severe vision impairment by superregion in 2020 in adults aged 
50 years and older
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eastern sub-Saharan Africa, southeast Asia, Oceania, and 
north Africa and Middle East. Cataract and undercorrected 
refractive error contributed similarly in central Asia, 
Andean Latin America, east Asia, and south Asia; 
undercorrected refractive error was the largest contributor 
everywhere else.
Age-standardised prevalence of blindness for all 
modelled causes consistently showed a regional 
decrease between 1990 and 2020 (figure 3). The notable 
exception to this trend was diabetic retinopathy, for 
which prevalence increased in many regions, with the 
largest increase in southern sub-Saharan Africa 
(percentage change 138·3% [113·0–168·5]). The pattern 
for MSVI was less consistent, with regional variation of 
increased, decreased, or no change to age-standardised 
prevalence between 1990 and 2020 for all modelled 
causes (appendix p 8). All age estimates and crude 
prevalence by sex are shown in the appendix (pp 3–5).
For myopic macular degeneration, we only produced 
estimates in China because of data sparsity. In 2020, the 
all-age crude prevalence of vision loss due to myopic 
macular degeneration was 0·02% (95% UI 0·01–0·03) 
for blindness and 0·21% (0·14–0·31) for MSVI. The 
number of people blind due to myopic macular 
degeneration increased by approximately 200% from 
0·103 million (95% UI 0·0678–0·154) people in 1990 to 
0·310 million (0·203–0·472) people in 2020. The number 
of people with MSVI due to myopic macular degeneration 
increased by approximately 340% from 0·659 million 
(0·433–1·01) people in 1990 to  2·93 million (1·96–4·38) 
people in 2020. In 2020, blindness due to myopic macular 
degeneration was more prevalent than blindness due to 
diabetic retinopathy (0·232 million people [0·156–0·348]), 
and similar to age-related macular degeneration 
(0·327 million people [0·226–0·447], while MSVI due to 
myopic macular degeneration was more prevalent than 
diabetic retinop athy (0·882 million people [0·632–1·18]), 
glaucoma (0·889 million people [0·700–1·11]), and 
Figure 2: Relative contribution of each cause to crude prevalence of blindness and moderate and severe vision 
impairment in 2020 by age group
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Figure 1: Age-specific prevalence rates of distance blindness and MSVI by cause and sex in adults aged 50 years and older in 2020 
Solid lines show sex-specific prevalence estimates, with shaded areas indicating 95% uncertainty intervals. MSVI=moderate to severe vision impairment.
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age-related macular degeneration (2·36 million people 
[1·88–2·89]). 
Discussion
Our results show that both cataract and undercorrected 
refractive error are among the three leading causes of 
blindness and MSVI in 2020. We estimate that 
worldwide there are over 15 million adults aged 50 years 
and older who are blind due to cataract, and more than 
86 million who have MSVI due to undercorrected 
refractive error. In 2020, blindness due to cataract and 
undercorrected refractive error composes 50% of all 
global blindness, and MSVI due to cataract and 
undercorrected refractive error composes 75% of all 
global MSVI. The burden of total blindness due to 
cataract and undercorrected refractive error has notable 
regional variability, but it has not been fully addressed 
in any world region, inclu ding high-income regions. 
The other main causes—glaucoma, age-related macular 
degeneration, and diabetic retinopathy—collectively 
contribute to over 6 million blind adults aged 50 years 
and older and over 13 million adults aged 50 years and 
older with MSVI in 2020. With the exception of diabetic 
retinopathy, age-standardised prevalence due to all of 
the causes of blindness we report here has decreased 
between 1990 and 2020. Given that the vast majority of 
vision impairment and blindness caused by cataract, 
undercorrected refractive error, diabetic retinopathy, 
Figure 3: Change in regional age-standardised prevalence of blindness between 1990 and 2020 in adults aged 50 years and older, by cause of blindness
Data for moderate and severe vision impairment are presented in appendix (p 8).
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and glaucoma can be avoided with early detection and 
timely intervention, a large potential in reducing 
morbidity for these causes remains.
The WHA defined cataracts and refractive error as 
avoidable causes of vision impairment because they 
are so effectively treated with surgery and spectacles, 
respectively. The WHA GAP set a target of a 25% reduction 
in crude prevalence of avoidable vision impairment from 
2010 to 2019. It specifically highlighted the importance of 
reducing avoidable vision impairment prevalence in 
those aged 50 years and older given the majority of vision 
impairment occurs at older ages.8 We estimated that there 
has been an increase in all-age prevalence of avoidable 
vision impairment and no change in prevalence for adults 
aged 50 years and older during this time period, 
demonstrating that the WHA GAP goal was not met. This 
lack of change was driven primarily by almost no change 
in crude and age-standardised prevalence of avoidable 
MSVI, and a lower-than-necessary decrease in the age-
standardised prevalence of avoidable blindness. Cases of 
avoidable blindness and MSVI both increased in people 
aged 50 years and older. We therefore note that the GAP 
target was not met and that ageing populations and the 
strong association between vision impairment and age 
were an important barrier in reaching the target. With 
increasing need for prevention and treatment, eye care 
services have not managed to sufficiently keep up with 
demand to meet the target. However, the fact that the 
change in crude prevalence was better for avoidable 
blindness (–14·4%) than for avoidable MSVI (1·6%) 
suggests that the resources put into reducing blindness 
and visual impairment have been appropriately targeted 
at reducing blindness ahead of MSVI.
In 2020, cataract remained the first or second leading 
cause of blindness and MSVI in all world regions.1 
Cataract can at present only be treated operatively, by a 
trained surgeon within a system that has capacity to 
deliver surgeries and manage any postoperative 
complications. Alleviation efforts have taken the form 
of mass campaigns, especially in remote areas, and 
increasing the capacity for and accessibility of surgical 
services. Because prevalence increases with age, and is 
higher in women than in men, it remains an important 
focus for vision loss alleviation and for addressing gender 
equity. Outreach screening has been shown to enhance 
equity of access among underserved groups such as 
women and the elderly.19 We therefore recommend 
developing robust eye care systems supplemented by 
community outreach as principal strategies.
Undercorrected refractive error is an important cause 
of vision impairment and is easily treatable by spectacles, 
contact lenses, or refractive surgery. Myopia, hyperopia, 
and astigmatism are the main causes of distance vision 
impairment. Uncorrected aphakia has greatly declined 
since 1990 because of the use of intraocular lenses during 
cataract surgery.20 Conversely, the prevalence of myopia 
has been rapidly increasing, especially in urban areas.21 
The development of refractive services, including the 
provision of affordable spectacles are the main strategies 
to address uncorrected refractive errors.
Although cataract and undercorrected refractive error 
accounted for the majority of blindness and MSVI, 
glaucoma, age-related macular degeneration, and diabetic 
retinopathy also caused moderate or worse vision impair-
ment in almost 20 million people aged 50 years and older 
in 2020. These diseases are not easily treatable.
Glaucoma was ranked as the second leading cause of 
blindness and fourth leading cause of MSVI, and 
therefore the most common cause of irreversible blind-
ness, and the second most common cause of irreversible 
MSVI. Glaucoma in eyes with dense cataract might not 
be detected, and therefore glaucoma-related irreversible 
blindness was probably undercounted. With respect to 
the prevention of glaucoma-related vision impairment, 
tonometry has not proven to be a useful screening 
technique and visual acuity assessment is not useful 
because vision impairment is a late symptom of glauco-
matous optic neuropathy.22 Once detected, therapy for 
glaucoma can arrest or slow its deterioration in the 
majority of cases,23 hence the importance of improving 
systems of surveillance, highlighting risk among family 
members of cases, and effectiveness of care once 
treatment is initiated.
The age-standardised prevalence of blindness due to 
age-related macular degeneration declined by almost 30% 
from 1990 to 2020. This decrease was probably associated 
with the widespread clinical introduction of anti-VEGF 
therapy for exudative age-related macular degeneration.24 
Since the majority of patients with age-related macular 
degeneration show the currently untreatable non-exu-
dative form that can progress to atrophy of the foveal 
centre (geographic atrophy), the development of treat-
ments and prophylactic measures specifically against 
non-exudative age-related macular degeneration are 
warranted.
Although diabetic retinopathy was the smallest 
contributor to blindness in 2020 compared with under-
corrected refractive error, cataract, age-related macular 
degeneration, and glaucoma, it was the only cause of 
blindness that showed a global increase in age-
standardised prevalence between 1990 and 2020. With a 
projected more than 600 million people living with 
diabetes by 2040,25 and because people with diabetes live 
increasingly longer, the number of people with diabetic 
retinopathy and resulting vision impairment is expected 
to rapidly rise.26,27 Our study shows that diabetic 
retinopathy continues to be an identifiable cause of vision 
impairment. This is of particular concern in younger, 
economically active age groups. Our study also shows 
regional differences in temporal change of blindness due 
to diabetic retinopathy, with increases in many regions of 
Asia and sub-Saharan Africa, as well as high-income 
North America. Of concern is that, in comparison with 
cataract and undercorrected refractive error, the 
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management of severe diabetic retinopathy requires a 
disproportionate amount of resources, including 
availability of ophthalmologists who are trained in laser 
and surgery.28,29
The strengths of this updated review and analysis 
for 2020 include the substantial addition of new data 
sources disaggregated by cause and the wider geo graphical 
region that these sources cover. In particular, the addition 
of new RAAB surveys improved geographic coverage, and 
the age disaggregation of many of these surveys improved 
the fitting of age patterns to the data. However, there 
remain several regions such as central sub-Saharan Africa, 
central and eastern Europe, and central Asia, with little or 
no population-based data where estimates rely on 
extrapolation from other regions. There are surprisingly 
few data from high-income regions—only 19 studies 
included here reported cause-specific vision impairment 
in a high-income location, and all but three of these took 
place more than a decade ago. Sparse data also limited the 
certainty of estimates of temporal trends and age patterns, 
particularly in children and young adults for undercorrected 
refractive error. Minimum ages set for inclusion of data by 
different causes was agreed with members of the VLEG 
but this consensus approach could be considered a 
limitation. A considerable proportion of the blindness 
burden was listed as “residual causes”. This “other” 
category is the result of a number of factors such as surveys 
not committing to a cause for each reported case of vision 
loss, the truncated list of causes given in published 
materials, and causes for which we have very limited data 
such as onchocerciasis, trachoma, xerophthalmia, ocular 
trauma, corneal diseases, amblyopia, and retinopathy of 
prematurity. With trachoma, for example, WHO reports 
that the numbers at risk have dropped from 1·5 billion 
in 2002 to 142 million in 2019 and the number with 
trichiasis from 7·6 million to 2·5 million.30 RAAB studies 
were adjusted to reference non-RAAB studies using 
adjustments generated for all-causes of MSVI and 
blindness impairment combined because these models 
were more data rich. However, these adjustments might 
not be the same for conditions affecting the fundus. 
Regional-level data might be misleading by masking 
the diversity of existing situations within countries and 
even within communities.31,32 Greater sociodemographic 
granularity in data collection is needed to identify 
populations at risk and capture actual progress in the 
provision of equitable eye care services.
This report highlights a need for more data on the 
causes of vision impairment, where we found data 
sources to be sparse, particularly in children and young 
adults, high-income locations, and in sub-Saharan Africa. 
The development of RAABs has led to increasing coverage 
of low-income and middle-income countries, but not 
for younger age groups. Also, up-to-date, population-
representative data from high-income settings has lagged 
behind. Better age and geographical data coverage would 
allow for more detailed analyses of individual country 
differences and a breakdown of which diseases most 
impact vision in children.
This report represents a major update of global and 
regional data on the causes of prevalence of blindness 
and vision impairment and adds to our understanding of 
temporal change over 30 years. Over the past decade the 
prevalence of avoidable visual impairment has decreased 
in adults aged 50 years and older, but it has not reached 
the targeted 25% reduction delineated in the WHA GAP. 
The principal reason from a global perspective is the 
failure of eye care services to keep pace with the ageing 
and growth of populations, yet the reduction in age-
standardised prevalence of blindness due to causes 
such as cataract, glaucoma, age-related macular degen-
era tion, and undercorrected refractive error was a 
reassuring change in the right direction. The report 
demonstrates the considerable inter-regional differences 
that exist and highlights areas which require particular 
attention, such as blindness due to diabetic retinopathy, 
which was the only cause to increase in age-standardised 
blindness prevalence over three decades.
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